<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04406324</url>
  </required_header>
  <id_info>
    <org_study_id>38RC20.157</org_study_id>
    <nct_id>NCT04406324</nct_id>
  </id_info>
  <brief_title>COVID-19: Respiratory and Sleep Follow-up</brief_title>
  <acronym>Co-SURVIVORS</acronym>
  <official_title>COVID-19: Prospective Follow-up of Pulmonary Function, Sleep Disorders, Quality of Life and Post-traumatic Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current project is a prospective, multicentric cohort study aiming at a multidisciplinary&#xD;
      assessment (pulmonary, cardiometabolic, sleep and mental health) of the consequences of&#xD;
      infection by SARS-CoV-2, 3 months after the diagnosis in order to better characterize these&#xD;
      complications. 400 patients with a positive diagnosis of SARS-CoV-2 will be included in the&#xD;
      study 3 months after their diagnosis: They will be followed at 6 months, 1 year, 3 years, and&#xD;
      5 years, as function of their after-effects discovered at 3 months and their evolution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Europe and in particular Italy, Spain and France are currently affected by the coronavirus&#xD;
      2019-nCoV pandemic, whose immediate prognosis is linked to the development of acute&#xD;
      respiratory distress syndrome (ARDS). Beyond the long-term adverse effects on respiratory&#xD;
      health and reduced exercise capacity, other complications will occur. These include a more&#xD;
      rapid progression of cardiometabolic diseases, a secondary epidemic of disabling&#xD;
      post-traumatic stress disorder, and severe sleep disorders. The current project aims at a&#xD;
      multidisciplinary assessment of respiratory, cardiac, sleep and mental health sequelae, three&#xD;
      months after SARS-CoV-2 diagnosis in order to better characterize these complications.&#xD;
&#xD;
      Three aspects will be targeted in this study : (i) long-term monitoring of deterioration in&#xD;
      lung function, (ii) screening for sleep respiratory disorders (sleep apnea syndrome, obesity&#xD;
      hypoventilation syndrome) and iii) characterization of sleep disorders and design of&#xD;
      specialized intervention to improve sleep quality.&#xD;
&#xD;
      This study is a prospective, multicentric cohort study that aims at constituting a cohort of&#xD;
      400 patients who will be screened for pulmonary, cardiac, sleep, or psychological sequelae 3&#xD;
      months after their diagnosis. They will be then followed for 5 years. The primary outcome&#xD;
      will be the diffusion capacity of carbon monoxide (DLCO) 3 months after the diagnosis. Other&#xD;
      secondary outcomes will include:&#xD;
&#xD;
        -  prevalence of sleep disorders and sleep disordered breathing 3 months after diagnosis&#xD;
           and their evolution until 5 years;&#xD;
&#xD;
        -  prevalence of cardiac, exercise capacity, respiratory and ventilatory muscles&#xD;
           impairments at 3 months and their evolution until 5 years;&#xD;
&#xD;
        -  characterization of homogeneous groups of patients who were infected with SARS-CoV-2 and&#xD;
           have respiratory, cardiometabolic and/or sleep complications, 3 months after diagnosis&#xD;
           (latent class analysis) and evaluate their evolution until 5 years&#xD;
&#xD;
        -  determine the prevalence of radiological sequelae at 3 months, and their evolution until&#xD;
           5 years&#xD;
&#xD;
        -  determine the psycho-social impact (quality of life, post-traumatic stress, anxiety,&#xD;
           productivity at work) at 3 months and its evolution until 5 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">March 5, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diffusion Capacity for Carbon Monoxide (CO) 3 months after COVID diagnosis</measure>
    <time_frame>3 months after COVID diagnosis</time_frame>
    <description>Pulmonary function 3 months after COVID diagnosis, as measured by diffusion capacity of carbon monoxide (DLCO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Sleep Disordered Breathing (SDB) 3 months after COVID diagnosis</measure>
    <time_frame>3 months after COVID diagnosis</time_frame>
    <description>Prevalence of Sleep Disordered Breathing, as measured by polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of sleep disorders 3 months after COVID diagnosis</measure>
    <time_frame>3 months after COVID diagnosis</time_frame>
    <description>Prevalence of sleep disorders, as measured by polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of ventilatory muscle function impairments, 3 months after COVID diagnosis</measure>
    <time_frame>3 months after COVID diagnosis</time_frame>
    <description>Prevalence of ventilatory impairments measured by pulmonary function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of cardiac impairments 3 months after COVID diagnosis</measure>
    <time_frame>3 months after COVID diagnosis</time_frame>
    <description>Prevalence of cardiac impairments measured by cardiac echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up of pulmonary diffusion capacity of carbon monoxide</measure>
    <time_frame>From Baseline (3 months after COVID diagnosis) to 5 years</time_frame>
    <description>Pulmonary function as measured by diffusion capacity of carbon monoxide (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up of sleep disorders treatment compliance</measure>
    <time_frame>From Baseline (3 months after COVID diagnosis) to 5 years</time_frame>
    <description>Assessment of SDB treatments adherence will be monitored in hours/night</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up of sleep disorders treatments efficacy</measure>
    <time_frame>From Baseline (3 months after COVID diagnosis) to 5 years</time_frame>
    <description>Assessment of SDB treatments efficacy will be based on the residual AHI index (Apnea Hypopnea/hour) under treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HLA alleles aspect of COVID clinical presentation</measure>
    <time_frame>3 months after COVID diagnosis</time_frame>
    <description>HLA alleles will be assessed as a component of genetic immune capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KIR loci aspect of COVID clinical presentation</measure>
    <time_frame>3 months after COVID diagnosis</time_frame>
    <description>KIR loci will be assessed as a different component of genetic immune capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolomic aspect of COVID clinical presentation</measure>
    <time_frame>3 months after COVID diagnosis</time_frame>
    <description>metabolome expression in sera</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>SARS-CoV-2 patients</arm_group_label>
    <description>Patients infected by SARS-CoV-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No Intervention. The study consists in a prospective clinical longitudinal follow-up</description>
    <arm_group_label>SARS-CoV-2 patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected by SARS-CoV-2&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female, aged &gt; 18 years&#xD;
&#xD;
          -  With a positive diagnosis for SARS-COVID-19, confirmed by RT-PCR or with compatible&#xD;
             symptoms&#xD;
&#xD;
          -  Signed informed consent by patient&#xD;
&#xD;
          -  Affiliated to a French social and health insurance system or equivalent&#xD;
&#xD;
          -  For biological collection: patient eligible for sampling (weight &gt;50kg and hemoglobin&#xD;
             &gt;7g/dL) and signed inform consent for collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Prisoners or patients who require protection by the law&#xD;
&#xD;
          -  Patients not affiliated to a French social and health insurance system or equivalent&#xD;
&#xD;
          -  Ages &lt;18 years&#xD;
&#xD;
          -  Diagnosis of infection by other pathogen than SARS-COVID-19 or no indication of&#xD;
             infection by COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud Tamisier, MD, PhD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Grenoble Aples</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renaud Tamisier, MD, PhD, MBA</last_name>
    <phone>+33 476 768 469</phone>
    <email>rtamisier@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Planes, MD, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Henri Mondor, APHP</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Derumeaux, MD, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud Tamisier, MD, Pr, PhD</last_name>
      <phone>(0033)476768469</phone>
      <email>rtamisier@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Louis Pepin, MD, Pr, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sam Bayat, MD, Pr, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Laure Mounayar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Terzi, MD, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Destors, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Chenuel, MD, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, Ko FW, Chan MC, Chan DP, Tong MW, Rainer TH, Ahuja AT, Cockram CS, Sung JJ. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005 May;60(5):401-9. doi: 10.1136/thx.2004.030205.</citation>
    <PMID>15860716</PMID>
  </reference>
  <reference>
    <citation>Burnham EL, Hyzy RC, Paine R 3rd, Coley C 2nd, Kelly AM, Quint LE, Lynch D, Janssen WJ, Moss M, Standiford TJ. Chest CT features are associated with poorer quality of life in acute lung injury survivors. Crit Care Med. 2013 Feb;41(2):445-56. doi: 10.1097/CCM.0b013e31826a5062.</citation>
    <PMID>23263616</PMID>
  </reference>
  <reference>
    <citation>Herridge MS, Moss M, Hough CL, Hopkins RO, Rice TW, Bienvenu OJ, Azoulay E. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 2016 May;42(5):725-738. doi: 10.1007/s00134-016-4321-8. Epub 2016 Mar 30.</citation>
    <PMID>27025938</PMID>
  </reference>
  <reference>
    <citation>Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JM, Mercat A, Brochard L, Brun-Buisson C, Chastre J; REVA Study Group. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012 Sep;142(3):583-592. doi: 10.1378/chest.11-2196.</citation>
    <PMID>22948576</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Pulmonary function</keyword>
  <keyword>Sleep disorders</keyword>
  <keyword>Post-traumatic stress</keyword>
  <keyword>Cardiac function</keyword>
  <keyword>Sleep Apnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04406324
org study id: 38RC20.157
nct id: NCT04406324
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The current project is a prospective, multicentric cohort study aiming at a multidisciplinary
      assessment (pulmonary, cardiometabolic, sleep and mental health) of the consequences of
      infection by SARS-CoV-2, 3 months after the diagnosis in order to better characterize these
      complications. 400 patients with a positive diagnosis of SARS-CoV-2 will be included in the
      study 3 months after their diagnosis: They will be followed at 6 months, 1 year, 3 years, and
      5 years, as function of their after-effects discovered at 3 months and their evolution.
Europe and in particular Italy, Spain and France are currently affected by the coronavirus
      2019-nCoV pandemic, whose immediate prognosis is linked to the development of acute
      respiratory distress syndrome (ARDS). Beyond the long-term adverse effects on respiratory
      health and reduced exercise capacity, other complications will occur. These include a more
      rapid progression of cardiometabolic diseases, a secondary epidemic of disabling
      post-traumatic stress disorder, and severe sleep disorders. The current project aims at a
      multidisciplinary assessment of respiratory, cardiac, sleep and mental health sequelae, three
      months after SARS-CoV-2 diagnosis in order to better characterize these complications.

      Three aspects will be targeted in this study : (i) long-term monitoring of deterioration in
      lung function, (ii) screening for sleep respiratory disorders (sleep apnea syndrome, obesity
      hypoventilation syndrome) and iii) characterization of sleep disorders and design of
      specialized intervention to improve sleep quality.

      This study is a prospective, multicentric cohort study that aims at constituting a cohort of
      400 patients who will be screened for pulmonary, cardiac, sleep, or psychological sequelae 3
      months after their diagnosis. They will be then followed for 5 years. The primary outcome
      will be the diffusion capacity of carbon monoxide (DLCO) 3 months after the diagnosis. Other
      secondary outcomes will include:

        -  prevalence of sleep disorders and sleep disordered breathing 3 months after diagnosis
           and their evolution until 5 years;

        -  prevalence of cardiac, exercise capacity, respiratory and ventilatory muscles
           impairments at 3 months and their evolution until 5 years;

        -  characterization of homogeneous groups of patients who were infected with SARS-CoV-2 and
           have respiratory, cardiometabolic and/or sleep complications, 3 months after diagnosis
           (latent class analysis) and evaluate their evolution until 5 years

        -  determine the prevalence of radiological sequelae at 3 months, and their evolution until
           5 years

        -  determine the psycho-social impact (quality of life, post-traumatic stress, anxiety,
           productivity at work) at 3 months and its evolution until 5 years
observational model: Cohort
time perspective: Prospective
measure: Diffusion Capacity for Carbon Monoxide (CO) 3 months after COVID diagnosis
time frame: 3 months after COVID diagnosis
description: Pulmonary function 3 months after COVID diagnosis, as measured by diffusion capacity of carbon monoxide (DLCO)
measure: Prevalence of Sleep Disordered Breathing (SDB) 3 months after COVID diagnosis
time frame: 3 months after COVID diagnosis
description: Prevalence of Sleep Disordered Breathing, as measured by polysomnography
measure: Prevalence of sleep disorders 3 months after COVID diagnosis
time frame: 3 months after COVID diagnosis
description: Prevalence of sleep disorders, as measured by polysomnography
measure: Prevalence of ventilatory muscle function impairments, 3 months after COVID diagnosis
time frame: 3 months after COVID diagnosis
description: Prevalence of ventilatory impairments measured by pulmonary function tests
measure: Prevalence of cardiac impairments 3 months after COVID diagnosis
time frame: 3 months after COVID diagnosis
description: Prevalence of cardiac impairments measured by cardiac echography
measure: Follow-up of pulmonary diffusion capacity of carbon monoxide
time frame: From Baseline (3 months after COVID diagnosis) to 5 years
description: Pulmonary function as measured by diffusion capacity of carbon monoxide (DLCO)
measure: Follow-up of sleep disorders treatment compliance
time frame: From Baseline (3 months after COVID diagnosis) to 5 years
description: Assessment of SDB treatments adherence will be monitored in hours/night
measure: Follow-up of sleep disorders treatments efficacy
time frame: From Baseline (3 months after COVID diagnosis) to 5 years
description: Assessment of SDB treatments efficacy will be based on the residual AHI index (Apnea Hypopnea/hour) under treatment
measure: HLA alleles aspect of COVID clinical presentation
time frame: 3 months after COVID diagnosis
description: HLA alleles will be assessed as a component of genetic immune capacity
measure: KIR loci aspect of COVID clinical presentation
time frame: 3 months after COVID diagnosis
description: KIR loci will be assessed as a different component of genetic immune capacity
measure: metabolomic aspect of COVID clinical presentation
time frame: 3 months after COVID diagnosis
description: metabolome expression in sera
arm group label: SARS-CoV-2 patients
description: Patients infected by SARS-CoV-2
intervention type: Other
intervention name: No intervention
description: No Intervention. The study consists in a prospective clinical longitudinal follow-up
arm group label: SARS-CoV-2 patients
Blood, Urine
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Renaud Tamisier, MD, PhD, MBA
role: Principal Investigator
affiliation: University Hospital Grenoble Aples
last name: Renaud Tamisier, MD, PhD, MBA
phone: +33 476 768 469
email: rtamisier@chu-grenoble.fr
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
country: France
citation: Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
PMID: 32031570
citation: Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, Ko FW, Chan MC, Chan DP, Tong MW, Rainer TH, Ahuja AT, Cockram CS, Sung JJ. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005 May;60(5):401-9. doi: 10.1136/thx.2004.030205.
PMID: 15860716
citation: Burnham EL, Hyzy RC, Paine R 3rd, Coley C 2nd, Kelly AM, Quint LE, Lynch D, Janssen WJ, Moss M, Standiford TJ. Chest CT features are associated with poorer quality of life in acute lung injury survivors. Crit Care Med. 2013 Feb;41(2):445-56. doi: 10.1097/CCM.0b013e31826a5062.
PMID: 23263616
citation: Herridge MS, Moss M, Hough CL, Hopkins RO, Rice TW, Bienvenu OJ, Azoulay E. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 2016 May;42(5):725-738. doi: 10.1007/s00134-016-4321-8. Epub 2016 Mar 30.
PMID: 27025938
citation: Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JM, Mercat A, Brochard L, Brun-Buisson C, Chastre J; REVA Study Group. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012 Sep;142(3):583-592. doi: 10.1378/chest.11-2196.
PMID: 22948576
responsible party type: Sponsor
mesh term: COVID-19
sharing ipd: Undecided